Gland Pharma Ltd
Gland Pharma | 543245
Stock Performance
Ratios
About Company
- Gland Pharma Limited was incorporated as Gland Pharma Private Limited', a private limited company on March 20, 1978 and was granted the certificate of incorporation by Registrar of Companies, Andhra Pradesh at Hyderabad
- Subsequently, the name of the Company was changed to Gland Pharma Limited' and a fresh certificate of incorporation dated April 25, 1995 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad
- The Company is primarily engaged in manufacturing injectable formulations
- Established in Hyderabad, India, Company has evolved into a prominent entity in the global generic injectables market, with operations extending to over 60 countries including the United States, Europe, Canada, Australia, and India
- Primarily functioning under a B2B model, the company provides comprehensive services such as contract development, dossier compilation, technology transfer, and manufacturing across various delivery systems
- Over the years, the company has made substantial investments in the companies manufacturing infrastructure to support the product portfolio needs and reach
- The company has seven manufacturing facilities in India, comprising four finished formulations facilities with a total of 42 production lines and three API facilities
- The companies API facilities provide with in-house manufacturing capabilities for critical APIs, enabling the company to control costs and quality and mitigate supply chain related risks around the key products
- The companies capabilities as a vertically integrated company include internal research and development (R&D) expertise, robust manufacturing capabilities, a strict quality assurance system, extensive regulatory experience and established marketing and distribution relationships
- As of March 31, 2020, the company along with partners had 265 ANDA filings in the United States, of which 204 were approved and 61 were pending approval
Technical Indicators
Pivot Points
Volume Analysis
Growth Rate
All figures in ₹ Crores
No Information Available
No shareholding data available at this time.
No Data Available
No Block Deals data available for this company.
News
No Information Available
Peers
#IndiaInvests
Trusted by 2.5 lac + Indians for their wealth-building needs
Invest in stocks with ease
Open your account in less than 10 mins*
By proceeding, you agree to all T&C *
Frequently Asked Questions
What is Share Price of Gland Pharma Ltd?
The current share price of Gland Pharma Ltd (Gland Pharma) is ₹1815.30. This price reflects the latest market valuation and is updated in real-time during trading hours.
What is the P/E Ratio of Gland Pharma Ltd?
The Price-to-Earnings (P/E) ratio of Gland Pharma Ltd is 1815.30. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.
What is the 52-week high and low of Gland Pharma Ltd?
Gland Pharma Ltd has a 52-week high of ₹2131.00 and a 52-week low of ₹1277.80. This range shows the stock's price volatility over the past year.
What is the Dividend Yield of Gland Pharma Ltd?
Gland Pharma Ltd offers a dividend yield of 0.98%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.
What is the EPS of Gland Pharma Ltd?
The Earnings Per Share (EPS) of Gland Pharma Ltd is ₹47.97. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.
What is the ROE of Gland Pharma Ltd?
Gland Pharma Ltd has a Return on Equity (ROE) of 11.62%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.
Disclaimer:
Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.
